Tevogen Bio Holdings Inc. Cash Flow Conversion Efficiency
Tevogen Bio Holdings Inc. cash flow conversion efficiency. Based on the latest financial reports, Tevogen Bio Holdings Inc. (TVGN) has a cash flow conversion efficiency ratio of 0.338x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.01 Million) by net assets ($-8.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tevogen Bio Holdings Inc. (2022–2026)
Cash flow conversion efficiency of Tevogen Bio Holdings Inc. from 2022 to 2026. This chart illustrates how Tevogen Bio Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tevogen Bio Holdings Inc. (TVGN) stock price for real-time trading data and today's change.
Tevogen Bio Holdings Inc. Cash Flow Conversion Ratio Explained
Tevogen Bio Holdings Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tevogen Bio Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tevogen Bio Holdings Inc. ranked by their cash flow conversion efficiency. Also see TVGN market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ariana Resources Plc
AU:AA2
|
-0.024x |
|
Coventry Group Ltd
AU:CYG
|
0.024x |
|
WESTBRIDGE RE. EN. CORP.
F:PUQ
|
N/A |
|
Pacific Orient Bhd
KLSE:6009
|
-0.205x |
|
I Yuan Precision Ind Co Ltd
TWO:2235
|
0.005x |
|
Senstar Technologies Ltd
NASDAQ:SNT
|
0.042x |
|
GP Petroleums Limited
NSE:GULFPETRO
|
0.039x |
|
Eternal Energy Public Company Limited
BK:EE
|
-0.078x |
Annual Cash Flow Conversion Efficiency for Tevogen Bio Holdings Inc. (2022–2026)
The table below shows the annual cash flow conversion efficiency of Tevogen Bio Holdings Inc. from 2022 to 2026. Review Tevogen Bio Holdings Inc. financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $-8.23 Million | $-12.33 Million | 1.497x | -16.72% |
| 2025-06-30 | $-6.67 Million | $-12.00 Million | 1.798x | +1977.65% |
| 2024-06-30 | $-94.43 Million | $-8.17 Million | 0.087x | -66.06% |
| 2023-06-30 | $-33.95 Million | $-8.66 Million | 0.255x | -20.31% |
| 2022-06-30 | $-16.49 Million | $-5.27 Million | 0.320x | -- |
About Tevogen Bio Holdings Inc.
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B… Read more